Monensin has been reported to suppress many cancer-related pathways such as those involving β-catenin/Wnt, E2F/DP1, STAT1/2, NFkB, AP-1 and Elk-1/SRF, and to downregulate EGFR expression, especially in pancreatic cancer lines [114,115]. Here, EGFR is linked to cancer.